Pittenger & Anderson Inc Halozyme Therapeutics, Inc. Transaction History
Pittenger & Anderson Inc
- $2.5 Billion
- Q3 2024
A detailed history of Pittenger & Anderson Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Pittenger & Anderson Inc holds 77 shares of HALO stock, worth $3,895. This represents 0.0% of its overall portfolio holdings.
Number of Shares
77Holding current value
$3,895% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
509Shares Held
125MCall Options Held
208KPut Options Held
77.1K-
Black Rock Inc. New York, NY17.6MShares$891 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$652 Million0.01% of portfolio
-
State Street Corp Boston, MA5.81MShares$294 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.04MShares$204 Million4.92% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.72MShares$188 Million0.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $7.05B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...